The US Food and Drug Administration (FDA) has granted de novo clearance to Claret Medical for commercialising its Sentinel cerebral protection system (CPS).

Developed to provide protection from the risk of stroke, the new CPS is designed to capture and remove debris ejected during transcatheter aortic valve replacement (TAVR) before it reaches the brain.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The data from a randomised controlled SENTINEL clinical trial indicated a 63% decrease in strokes during the first 72 hours following TAVR, while there was also a substantial difference at 90 days.

The new device is set to launch at select high-volume TAVR centres of excellence across the country.

SENTINEL trial clinical steering committee chairman Martin Leon said: “The fact that one in four patients had an average of 25 particles of debris collected that were visible to the naked eye is striking.

See Also:

“The device was delivered safely, added minimal time to the procedure, and performed as intended with capture of embolic material and reduction in ischemic brain injury.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"The data from a randomised controlled SENTINEL clinical trial indicated a 63% decrease in strokes during the first 72 hours following TAVR, while there was also a substantial difference at 90 days."

In 99% of TAVR cases, the device was found to eliminate visible debris that headed towards the brain, with no added risk, regardless of the replacement valve type.

The CPS enables positioning away from the aortic arch, which results in decreased interference with TAVR catheters, no damage to the aortic arch, while it allows physicians to focus on the procedure.

Claret Medical president and CEO Azin Parhizgar said: “By helping to reduce the occurrence of periprocedural strokes, we intend to provide patients and physicians with greater peace of mind as they approach a TAVR procedure.”

The Sentinel was assessed in more than 1,000 patients and has been used to protect more than 3,500 patients across the world.

Image: The Sentinel cerebral protection system. Photo: courtesy of Claret Medical Inc.